Recently, the Food and Drug Administration (FDA) approved nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) melanoma in adults, regardless of BRAF status. Here, BRAF is linked to melanoma.